Literature DB >> 3873975

Prekallikrein activation in the adult respiratory distress syndrome.

M Schapira, J P Gardaz, P Py, P D Lew, L H Perrin, P M Suter.   

Abstract

Prekallikrein is the zymogen form of plasma kallikrein, a proteolytic enzyme of the contact system of blood coagulation, fibrinolysis and kinin formation. To assess whether prekallikrein was activated in the adult respiratory distress syndrome (ARDS), we examined plasma samples from 12 critically ill patients including five individuals with ARDS. Using the ratio between functional prekallikrein and prekallikrein-kallikrein antigen as an index for prekallikrein activation, we found that prekallikrein was extensively activated in patients with ARDS, while this was significantly less in the case of critically ill patients without ARDS. Following activation of prekallikrein in plasma, kallikrein reacts with its substrates and with protease inhibitors, among which the alpha 2-glycoprotein C1-inhibitor. Thus, we examined whether C1-inhibitor of critically ill individuals was modified in a way suggesting that it had reacted with kallikrein. Such a modification was found in the five patients with ARDS, while it was not detectable in the seven patients without ARDS. This observation further confirmed the activation of prekallikrein in patients with ARDS. We suggest that plasma kallikrein-mediated reactions, which include bradykinin release and neutrophil activation, may contribute to the pathogenesis of ARDS.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3873975

Source DB:  PubMed          Journal:  Bull Eur Physiopathol Respir        ISSN: 0395-3890


  6 in total

1.  Bradykinin stimulates interleukin-8 production by human lung fibroblasts.

Authors:  R Hayashi; N Yamashita; S Matsui; M Maruyama; E Sugiyama; S Sugiyama; M Kobayashi
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

2.  PF-04886847 (an inhibitor of plasma kallikrein) attenuates inflammatory mediators and activation of blood coagulation in rat model of lipopolysaccharide (LPS)-induced sepsis.

Authors:  D Kolte; J W Bryant; G W Gibson; J Wang; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2012-06

3.  Recombinant alpha 1-antitrypsin Pittsburgh (Met 358----Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment.

Authors:  M Schapira; M A Ramus; S Jallat; D Carvallo; M Courtney
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

Review 4.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

5.  The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System.

Authors:  Miklós Lipcsey; Barbro Persson; Oskar Eriksson; Anna M Blom; Karin Fromell; Michael Hultström; Markus Huber-Lang; Kristina N Ekdahl; Robert Frithiof; Bo Nilsson
Journal:  Front Immunol       Date:  2021-02-22       Impact factor: 7.561

Review 6.  Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.

Authors:  B Solun; Y Shoenfeld
Journal:  Med Drug Discov       Date:  2020-06-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.